ASCO GU 2017: A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.

Orlando, Florida USA (UroToday.com) This study by Neal Shore et al examined the feasibility and safety of a novel DNA-based immunotherapy called INO-5150 in a cohort of patients with biochemically relapsed prostate cancer. This novel method of immunotherapy delivers synthetic antigens SynCon PSA and PSMA (INO-5150) with or without plasmid encoded IL-12 followed by electroporation using the CELLECTRA5P device to boost the host’s immune response in attacking residual prostate cancer cells. The study reported no Grade 4-5 adverse events. Grade 3 treatment emergent AEs occurred in 81% of the patients. The most common AEs were injection site pain (39%), erythema (21%), and swelling (19%).

This novel therapeutic modality has first shown efficacy in cervical cancer. The adoption of this strategy in prostate cancer stems from previous successes with immunotherapy in the metastatic prostate cancer setting. The preliminary results demonstrate promise and warrant further investigation.

First Author: Neal Shore

at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA

Login